Viread
HIV and AIDS: Antiretroviral Drugs, Treatments and Medications »
"Entry Inhibitors (including Fusion Inhibitors) and CCR5 Co-receptor Antagonist
Entry Inhibitors
Entry inhibitors block HIV entry into CD4+ cells.
Fusion inhibitors
The only drug in this class "...
Read the HIV and AIDS: Antiretroviral Drugs, Treatments and Medications article »
Viread
OVERDOSE
Limited clinical experience at doses higher than the therapeutic dose of VIREAD 300 mg is available. In Study 901, 600 mg tenofovir disoproxil fumarate was administered to 8 subjects orally for 28 days. No severe adverse reactions were reported. The effects of higher doses are not known.
If overdose occurs the patient must be monitored for evidence of toxicity, and standard supportive treatment applied as necessary.
Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of VIREAD, a four-hour hemodialysis session removed approximately 10% of the administered tenofovir dose.
CONTRAINDICATIONS
None.
Last reviewed on RxList: 4/22/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Viread Information
Viread - User Reviews
Viread User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Here is a collection of user reviews for the medication Viread sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
WebMD Daily
Get breaking medical news.
Updated & New
